


PRODUCT INFORMATION



Ramelteon

Item No. 20389

CAS Registry No.: 196597-26-9
Formal Name: N-[2-[(8S)-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]-propanamide
Synonym: TAK-375
MF: C₁₆H₂₁NO₂
FW: 259.3
Purity: ≥98%
UV/Vis.: λ_{max}: 286 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Ramelteon is supplied as a crystalline solid. A stock solution may be made by dissolving the ramelteon in the solvent of choice. Ramelteon is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of ramelteon in ethanol is approximately 25 mg/ml and approximately 30 mg/ml in DMSO and DMF.

Ramelteon is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ramelteon should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Ramelteon has a solubility of approximately 0.16 mg/ml in a 1:5 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Ramelteon is a melatonin (MT) receptor agonist (K_i = 14, 112, and 23.1 pM for human MT₁, human MT₂, and chick forebrain receptors, respectively).¹ It is selective for MT₁ and MT₂ over MT₃ receptors (K_i = 2.65 μM for hamster brain MT₃ receptors) as well as a panel of benzodiazepine, dopamine, and opiate receptors, ion channels, transporters, and enzymes when used at a concentration of 10 μM. Ramelteon stimulates cAMP production in CHO cells expressing human MT₁ and MT₂ receptors (IC₅₀s = 21.2 and 53.4 pM, respectively). *In vivo*, ramelteon (0.03 and 0.3 mg/kg, p.o.) shortens latency to sleep onset and increases duration of sleep in free-moving crab-eating macaques.² It also accelerates reentrainment of circadian rhythm in rats, shifting running wheel activity back to the dark period 2.4 and 3 days more quickly than vehicle-treated animals following an eight-hour phase shift in the light-dark cycle when administered at 0.1 and 1 mg/kg, respectively, with no effect on learning and memory in the Morris water maze and delayed match-to-position tasks.³

References

1. Kato, K., Hirai, K., Nishiyama, K., *et al.* Neurochemical properties of ramelteon (TAK-375), a selective MT₁/MT₂ receptor agonist. *Neuropharmacology* **48(2)**, 301-310 (2005).
2. Yukuhiro, N., Kimura, H., Nishikawa, H., *et al.* Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys. *Brain Res.* **1027(1-2)**, 59-66 (2004).
3. Hirai, K., Kita, M., Ohta, H., *et al.* Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. *J. Biol. Rhythms* **20(1)**, 27-37 (2005).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/02/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM